The Ivan Borrello Lab focuses on the development of a novel approach of adoptive T cell therapy utilizing marrow-infiltrating lymphocytes (MILs) as a more tumor-specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins and an exploration of this approach in other diseases, including nonhematologic malignancies. The lab also examines strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines.